

Updated 3/29/2023

											Updated 3/29/2023	
<b>Blood Banking/Transfusion Medicine Major Category Code Headings</b>												
1	Clinical Practice											10004
2	Histocompatibility and Tissue Banking											10500
3	RBCs and RBC Components											10800
4	Apheresis											11400
5	Hazards of Transfusion: Specific Adverse Events											11800
6	Plasma Components and Derivatives											12200
7	Infectious Hazards of Transfusion											12400
8	Blood Donors and Blood Collection											13000
9	Management, Quality, Legal, & Regulatory Issues in Transfusion Med. & Transplantation											13200
10	Surgery Patients											13500
11	Biovigilance											13900
12	Platelet and Platelet Components											14000
13	Neutrophils and Granulocyte Components											14100
14	Intravascular Cell Kinetics											14200
15	Obstetric and Pediatric Patients											14300
16	Hematopoietic Progenitor Cell (HPC) Transplantation											14500

											Cat Code
<b>Blood Banking/Transfusion Medicine</b>											10000
<b>1 Clinical Practice</b>											10004
<b>A Autoimmune Hemolytic Anemia</b>											10008
1 Classification, Epidemiology, and Causes											10012
2 Warm autoimmune hemolytic anemia											10016
a Pathophysiology											10020
b Autoantibodies and Specificity											10024
c Clinical Features											10028
d Laboratory Features											10032
e Treatment											10036
3 Cold Hemagglutinin Disease											10040
a Pathophysiology											10044
b Autoantibodies and Specificity											10048
c Clinical Features											10052
d Laboratory Features											10056
e Treatment											10060
4 Paroxysmal Cold Hemoglobinuria											10064
a Pathophysiology											10068
b Autoantibodies and Specificity											10072
c Clinical Features											10076
d Laboratory Features											10080
e Treatment											10084
5 Drug-Induced Immune Hemolytic Anemia											10088
a Drug Adsorption Mechanism											10092
b Drug-Dependent Antibody Mechanism											10096
c Autoimmune Induction Mechanism											10100
<b>B Paroxysmal Nocturnal Hemoglobinuria</b>											10104
1 Clinical Picture and Course											10108
2 Causes and Pathogenesis											10112
3 Laboratory Features											10116
4 Treatment											10120
5 Transfusions											10124
<b>C Anemia in Oncology Patients</b>											10128
1 Causes											10132
2 Clinical Features											10136
3 Management											10140
a Growth Factors											10144
b Transfusion Therapy											10148
<b>D Immune Thrombocytopenia</b>											10152
1 General Tests to Investigate Thrombocytopenia											10156
2 Platelet Antibody Assays (non-HIT)											10160
3 Tests for Heparin-Induced Thrombocytopenia											10164
4 Platelet genotyping											10168
5 Idiopathic (Immune) Thrombocytopenic Purpura											10172
a Pathogenesis											10176
b Clinical Features											10180
c Laboratory Features											10184
d Treatment											10188

					e	Immune Thrombocytopenic Purpura in Pregnancy	10192
					f	Acute Immune Thrombocytopenic Purpura of Childhood	10196
					g	Chronic Immune Thrombocytopenic Purpura of Childhood	10200
					h	Secondary Immune Thrombocytopenic Purpura	10204
			6			Drug-Induced Immune Thrombocytopenia	10208
					a	Heparin-Induced Thrombocytopenia	10212
						i Pathogenesis	10216
						ii Treatment and Management	10220
					b	Typical Drug-Induced Immune Thrombocytopenia	10224
					c	Atypical Drug-Induced Thrombocytopenic Purpura	10228
					d	Drug-Induced Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome	10232
			7			Alloimmune Thrombocytopenia	10236
					a	Platelet Alloantigens , Immunogenetics and Frequency of Alloimmune Thrombocytopenia	10240
					b	Neonatal Alloimmune Thrombocytopenia	10244
						i Pathophysiology and Clinical Features	10248
						ii Neonatal Treatment	10252
						iii Prenatal Management	10256
					c	Posttransfusion Purpura	10260
						i Pathophysiology and Clinical Features	10264
						ii Treatment	10268
					d	Passive Alloimmune Thrombocytopenia	10272
					e	Transplantation-Associated Alloimmune Thrombocytopenia	10276
						i Hematopoietic Transplantation	10280
						ii Solid organ Transplantation	10284
					f	Platelet Transfusion Refractoriness – Causes, Mechanisms and Management	10288
		E				Bleeding From Congenital and Acquired Coagulation Defects and Antithrombotic Therapy	10292
			1			Liver Disease	10296
					a	Pathophysiology	10300
					b	Laboratory Features	10304
					c	Management of Bleeding	10308
			2			Vitamin K Deficiency	10312
					a	Role of Vitamin K in Hemostasis	10316
					b	Hemorrhagic Disease of the Newborn	10320
					c	Other Causes of Vitamin K Deficiency	10324
					d	Treatment	10328
			3			Disseminated Intravascular Coagulation	10332
					a	Pathophysiology	10336
					b	Clinical Features	10340

				c	Laboratory Features			10344
				d	Treatment			10348
			4	Coagulation Factor Inhibitors				10352
				a	Factor VIII Inhibitors			10356
				b	Lupus Anticoagulants			10360
				c	Acquired von Willebrand Syndrome			10364
				d	Factor V Inhibitors			10368
				e	Acquired Factor X Deficiency			10372
				f	Other Coagulation Inhibitors			10376
			5	Acquired Platelet Function Disorders				10380
				a	Drug-Induced Platelet Dysfunction			10384
				b	Uremia			10388
				c	Cardiopulmonary Bypass			10392
			6	Antithrombotic Therapy				10396
				a	Warfarin			10400
				b	Heparin			10404
				c	Low Molecular Weight Heparins			10408
				d	Factor Xa Inhibitors			10412
				e	Direct Thrombin Inhibitors			10416
				f	Fibrinolytic Agents			10420
			7	Congenital Coagulopathies/Thrombophilias				10421
				a	Von Willebrand Disease			10422
				b	Factor Deficiencies, At III, Protein C, Protein S Deficiencies			10423
	F	Granulocyte Transfusion (Primarily Donor Issues)						10424
			1	Indications and Patient Selection				10428
			2	Donor Selection and Criteria				10432
			3	Donor Stimulation – Corticosteroids and G-CSF				10436
			4	Product Collection				10440
			5	Product Storage and Transport				10444
			6	Product Selection – Special Needs				10448
			7	Infusion and Monitoring				10452
			8	Adverse Events (Donor and Recipient)				10456
			9	Clinical Outcomes				10460
	G	Transfusion Risks and Reactions in Oncology						10464
			1	Infectious				10468
			2	Graft-Versus-Host Disease				10472
			3	Alloantibodies				10476
			4	Iron Overload				10480
2	Histocompatibility and Tissue Banking							10500
	A	HLA Antigens and Alleles						10504
			1	Major Histocompatibility Complex				10508
			2	Class I and II Antigens and Their Function				10512
			3	Polymorphism of HLA System and Nomenclature				10516
			4	Identification of HLA Antigens, Antibodies and Alleles				10520
				a	Serologic Methods			10524
				b	Cellular Methods			10528
				c	Nucleic Acid-Based Methods			10532
				d	Crossmatching			10534
			5	Genotypes, Phenotypes and Haplotypes				10536
			6	Medical and Biological Significance of HLA				10540

			a	Transplantation					10544
				i	Hematopoietic Progenitor Cell				10548
				ii	Solid Organ				10552
			b	Disease Association					10556
	B	Tissue banking							10560
			1	Human Allograft Applications					10564
			2	Tissue Donation					10568
				a	Living Donors				10572
				b	Deceased Donors				10576
				c	Referral for Donation				10580
			3	Organization of Tissue Banking in the United States					10584
			4	Public Attitudes Regarding Organ and Tissue Donation					10588
			5	Tissue Transplant-Transmissible Diseases					10592
			6	Tissue Donor Suitability and Tissue Transplant Risk Reduction					10596
				a	Donor History Screening				10600
				b	Donor Physical Assessment				10604
				c	Tissue Recovery Methods				10608
				d	Infectious Disease Testing				10612
				e	Tissue Sterilization				10616
			7	General Principles of Tissue Preservation and Clinical Use					10620
				a	Bone				10624
				b	Cartilage, Meniscus, Tendon, Ligament and Dura Mater				10628
				c	Skin				10632
				d	Ocular Tissue				10636
				e	Cardiovascular Tissue				10640
				f	Peripheral Nerve				10644
				g	Parathyroid				10648
				h	Reproductive Tissue				10652
					i	Semen			10656
					ii	Oocytes and Embryos			10660
					iii	Extraembryonic			10664
			8	Transfusion Service Support of Tissue Transplantation					10668
			9	Tissue Banking and Transplantation Oversight					10672
	C	Adoptive Immunotherapy							10676
			1	Immunotherapy Targets for Cancer					10680
			2	T-Cell Immunotherapy Targets for Infections					10684
			3	Types of Adoptive Immunotherapy					10688
				a	Non-specific T Cells				10692
				b	Antigen-Specific T Cell Therapies				10696
				c	Genetically-Modified T Cells				10700
			4	Approaches to Improving Cellular Immunotherapy					10704
			5	Adoptive Immunotherapy regulatory Issues					10708
	D	Gene Therapy in Transfusion Medicine							10712
			1	Targeted Genes					10716
			2	Vector Design					10720
			3	Viral Vectors					10724
			4	Adeno-Associated Virus					10728

		5	Adenoviral vectors						10732
		6	Non-Viral Gene Therapy						10736
		7	Clinical Protocols and Trials						10740
	E	Tissue Engineering and Regenerative Medicine							10744
		1	Overview						10748
		2	Skin						10752
		3	Blood Vessel						10756
		4	Bone						10760
		5	Cartilage						10764
		6	Urology						10768
		7	Cardiac						10772
		8	Corneal						10776
3	RBCs and RBC Components								10800
	A	Red Cell Production and Kinetics							10804
		1	Erythropoietin						10808
			a	Regulation of Production				10812	
			b	Interaction with and Effects on Erythroid Progenitor Cells				10816	
		2	Nutritional Requirements for Erythropoiesis					10820	
		3	Influence of Pathologic States on Erythropoiesis					10824	
	B	Oxygen Delivery and Use of Red Cells and Red Cell Substitutes for Oxygen Delivery							10828
		1	Regulation of Systemic Oxygen Delivery						10832
		2	Regulation of Regional Oxygen Delivery						10836
		3	Regulation of Oxygen Delivery in the Microcirculation						10840
			a	Red Cell Transfusion and the Microcirculation				10844	
			b	Effect of Red Cell Storage Changes on the Microcirculation (N Oxide)				10848	
		4	Oxygen carrying Red Cell Substitutes					10852	
			a	Hemoglobin-Based			10856		
			b	Perfluorocarbon-Based			10860		
	C	Red Cell Metabolism and Preservation							10864
		1	Metabolism						10868
			a	Glucose			10872		
			b	Alternative Substrates			10876		
			c	Regulation of Energy Metabolism			10880		
			d	Synthetic Processes			10884		
			e	Membrane Metabolism			10888		
		2	Red Cell Preservation in Transfusion Medicine					10892	
			a	General Principles			10896		
			b	Collection and Separation Procedures			10900		
			c	Anticoagulant-Nutrient Solutions			10904		
			d	Additive Solutions			10908		
			e	Additional Factors Influencing RBC Quality			10912		
			f	Functionality			10916		
			g	Rejuvenation			10920		
			h	Frozen Storage			10924		
			i	Validation of RBC Storage Systems			10928		
	D	Red Cell Immunology and Compatibility Testing							10932
		1	Red Cell Immunology						10936

					a	Immune Response – Components and Characteristics	10940
					b	Blood Group Antibodies - Physical Properties and Characteristics	10944
					c	Red Cell Antigen-Antibody Interactions	10948
					i	Direct Agglutination	10952
					ii	Hemolysis	10956
					iii	Antiglobulin test (DAT)	10960
			2	Compatibility Testing			10964
				a	Donor Testing	10968	
				b	Patient testing	10972	
				i	Sample Collection	10976	
				ii	ABO Typing	10980	
				iii	Rh Typing	10984	
				iv	Tests for Unexpected Antibodies	10988	
				v	Reagents Red Cells for Antibody Detection	10992	
				vi	Automated Pretransfusion testing	10996	
				vii	Additional Techniques	11000	
				viii	Molecular Techniques	11002	
				c	Principles of Antibody Identification	11004	
				d	Donor-Recipient Testing	11008	
				i	Prior Records Check	11012	
				ii	Selection of Blood for Transfusion	11016	
				iii	Serologic Crossmatch	11020	
				iv	Electronic Crossmatch	11024	
				v	Labeling	11028	
				vi	Issue	11032	
				vii	Emergency Release	11036	
				viii	Bedside Check	11040	
				ix	Hemovigilance	11044	
			E	Carbohydrate Blood Groups and Blood Group Systems			11048
			1	ABH Antigens			11052
				a	Biochemistry	11056	
				b	Antigenic variants	11060	
				c	Secretion	11064	
				d	Se and H genes	11068	
				e	H-Deficient Phenotypes and Genotypes	11072	
				f	Medical Implications of the ABH and Secretor Systems	11076	
				i	ABO-Incompatible Solid Organ Transplantation	11080	
				ii	ABO-Incompatible Hematopoietic Progenitor Cell Transplantation	11084	
			2	Lewis System			11088
			3	Ii System			11092
			4	P System			11096
			F	Rh and LW Blood Group Systems			11100
			1	Rh Blood Group System - General Information and Nomenclature			11104

			2	Rh Genes and Their Expressed Proteins						11108
			3	Molecular Basis for Rh Antigen Expression						11112
				a	D Antigen					11116
				b	C/c and E/e Antigens					11120
				c	RH Genotyping					11124
			4	Rh-membrane Complex						11128
			5	Rh Function						11132
			6	Immune Response to Rh						11136
				a	Medical Aspects					11140
				b	Serologic Aspects					11144
				c	Molecular Aspects					11148
			7	LW Blood Group System						11152
				a	General information					11156
				b	Genes and Their Expressed Proteins					11160
				c	Molecular Basis for Antigen Expression					11164
				d	LW Function					11168
		G		Other Protein Blood Group Systems						11172
			1	Kell and Kx Blood						11176
				a	Structure, Function, and Interaction of the Kell and XK Proteins					11180
				b	Kell - Transfusion Medicine Aspects					11184
					i	Transfusions				11188
					ii	Hemolytic Disease of the Fetus and Newborn				11192
				c	Kell Variants					11196
			2	Duffy						11200
				a	Structure and Function of the Duffy Protein					11204
				b	Duffy - Transfusion Medicine Aspects					11208
					i	Transfusions				11212
					ii	Hemolytic Disease of the Fetus and Newborn				11216
			3	Kidd						11220
				a	Structure and Function of the Kidd Protein					11224
				b	Kidd - Transfusion Medicine Aspects					11228
					i	Transfusions				11232
					ii	Hemolytic Disease of the Fetus and Newborn				11236
			4	MNS						11240
				a	Structure and Function of Glycophorins A and B					11244
				b	MNS - Transfusion Medicine Aspects					11248
			5	Diego						11252
			6	Gerbich						11256
			7	Colton and GIL						11260
			8	Lutheran						11264
			9	Indian, Xg, and Scianna						11268
			10	Chido/Rodgers						11272
			11	Knops						11276
			12	Cartwright, Dombrock, Cromer and JMH						11280
			13	OK and RAPH						11284



	H	Anemia and Red Blood Cell Transfusion				11288
		1	Physiologic Adaptations to Blood Loss and Anemia			11292
			a	Oxygen Transport Principles and Mechanisms		11296
			b	Adaptive Mechanisms in Anemia		11300
			c	Microcirculatory Effects of Anemia and Red Cell Transfusion		11304
			d	Pathophysiologic Processes and Anemia – Interactions		11308
		2	Clinical Outcomes of Anemia and Red Cell Transfusion			11312
			a	Risks of Anemia		11316
			b	Efficacy of Transfusion		11320
				i	Adults	11324
				ii	Children	11328
		3	Transfusion Guidelines			11332
		4	Red Cell Transfusions - Decision Making			11336
			a	Bleeding Patient		11340
			b	Surgical Patient		11344
			c	Chronic Anemia		11348
			d	Transfusion Threshold		11352
			e	Dose and Administration		11356
4	Apheresis					11400
	A	Apheresis: Principles and Technology of Hemapheresis				11404
		1	General Information and Principles			11408
		2	Current Devices and Technology			11412
		3	Donor Apheresis			11416
			a	Donor Care		11420
			b	Specific Products and Procedures		11424
			c	Adverse Effects on Donors and Recipients		11428
		4	Therapeutic Apheresis			11432
			a	Procedural and Technical Aspects		11436
				i	Substances Removed	11440
				ii	Volume Removed	11444
				iii	Replacement Fluids (Technical and Composition Details)	11448
				iv	Schedule of Procedures (Timing, Number, Location)	11452
				v	Equipment	11456
				vi	Vascular access	11460
				vii	Anticoagulant	11464
				viii	Oversight	11468
				ix	Adverse Effects	11472
	B	Therapeutic Plasma Exchange				11476
		1	General Principles			11480
			a	Mathematic Principles		11484
			b	Regulation of IgG Metabolism		11488
			c	Replacement Fluids (Clinical Aspects)		11492
			d	Selective Extraction of Plasma Components		11496
			e	Indication and Treatment Intensity Categories		11500
		2	Neurologic Disorders			11504
			a	Guillain-Barré Syndrome		11508

					b	Chronic Inflammatory Demyelinating Polyneuropathy	11512
					c	Peripheral neuropathy and Monoclonal Gammopathy	11516
					d	Myasthenia Gravis	11520
					e	Lambert-Eaton Myasthenic Syndrome	11524
					f	Neuromyotonia and Limbic Encephalitis	11528
					g	Stiff-Person Syndrome	11532
					h	Paraneoplastic Neurologic Syndromes	11536
					i	Nonneoplastic Disorders with Central nervous System Antibodies	11540
					j	Multiple Sclerosis	11544
			3			Hematologic and Oncologic Disorders	11548
					a	Monoclonal Proteins	11552
					b	Blood Cell Alloantibodies	11556
					c	Thrombotic Thrombocytopenic Purpura	11560
					d	Hemolytic Uremic Syndrome	11564
					e	Posttransfusion Purpura	11568
					f	Idiopathic (Immune) Thrombocytopenic Purpura	11572
					g	Autoimmune Hemolytic Anemia	11576
					h	Pure Red Cell Aplasia and Aplastic Anemia	11580
					i	Coagulation Factor Inhibitors	11584
			4			Rheumatic and Other Immunologic Disorders	11588
					a	Cryoglobulinemia	11592
					b	Rheumatoid Arthritis	11596
					c	Systemic Lupus Erythematosus	11600
					d	Systemic Vasculitis Polymyositis and Dermatomyositis	11604
					e	Goodpasture Syndrome	11608
					f	Rapidly Progressive Glomerulonephritis – Other	11612
					g	Solid Organ Transplantation	11616
					i	Rejection	11620
					ii	Disease Recurrence	11624
			5			Toxic and Metabolic Disorders	11628
					a	Hypercholesterolemia	11632
					b	Refsum's Disease	11636
					c	Drug Overdose and Poisoning	11640
					d	Acute Liver Failure	11644
		C				Specialized Therapeutic Hemapheresis and Phlebotomy	11648
			1			Red Cell Exchange	11652
					a	Principles and Techniques	11656
					b	Sickle Cell Disease	11660
					c	Acute and/or Emergent Complications – Indications and Management	11664
					d	Chronic Conditions or Preventive Strategies – Indications and Management	11668
					e	Malaria	11672
					f.	Babesiosis	11676

			2	Erythrocytapheresis and Therapeutic Phlebotomy	11680
				a Polycythemia Vera	11684
				b Secondary Erythrocytosis	11688
				c Hereditary Hemochromatosis	11692
			3	Therapeutic Platelet Apheresis	11696
				a Primary Thrombocytosis	11700
				b Secondary Thrombocytosis	11704
			4	Therapeutic White Cell Apheresis	11708
				a Hyperleukocytosis	11712
				b Inflammatory Bowel Disease	11716
			5	Extracorporeal Photochemotherapy	11720
				a Techniques and Mechanisms	11724
				b Cutaneous T-Cell Lymphoma	11728
				c Cardiac Allograft Rejection	11732
				d Graft-Versus-Host Disease	11736
			6	Selective Extraction of Low-Density Lipoproteins	11740
				a Principles, Indications, and Techniques	11744
5	Hazards of Transfusion: Specific Adverse Events				11800
	A	Hemolytic Transfusion Reactions			11804
		1	Incidence		11808
		2	Signs and Symptoms		11812
		3	Complications		11816
		4	Causes		11820
		5	Differential Diagnosis		11824
		6	Laboratory Investigation		11828
		7	Pathophysiology		11832
		8	Treatment		11836
		9	Prevention		11840
	B	Febrile, Allergic, and Nonimmune Transfusion Reactions			11844
		1	Febrile Nonhemolytic		11848
			a	Description and Characteristics	11852
			b	Causes	11856
			c	Diagnosis	11860
			d	Treatment	11864
			e	Prevention	11868
		2	Allergic		11872
			a	Description and Characteristics	11876
			b	Causes	11880
			c	Diagnosis	11884
			d	Treatment	11888
			e	Prevention	11892
		3	Anaphylactic and Anaphylactoid		11896
			a	Description and Characteristics	11900
			b	Causes	11904
			c	Diagnosis	11908
			d	Treatment	11912
			e	Prevention	11916
		4	Massive and Rapid Transfusion - Complications		11920
			a	Definitions and Description	11924
			b	Citrate Toxicity	11928

			c	Electrolyte and Acid/Base Disorders	11932
			d	Hypothermia	11936
			e	Microaggregate Reactions	11940
		5		Circulatory Overload	11944
			a	Description and Characteristics	11948
			b	Causes	11952
			c	Diagnosis	11956
			d	Treatment	11960
			e	Prevention	11964
		6		Toxic Reactions Resulting From Blood Manufacture or Processing	11968
			a	Hypotensive	11972
			b	Ocular	11976
			c	Plasticizer Toxicity	11980
			d	Dimethyl Sulfoxide Toxicity and Cryopreserved Progenitor Cells	11984
		7		Special Transfusion Settings	11988
			a	Granulocyte Transfusion	11992
			b	Autologous Transfusion	11996
	C			Transfusion-Associated Graft-Versus-Host Disease	12000
		1		Pathophysiology	12004
		2		Incidence	12008
		3		Risk Factors - General	12012
		4		Fetuses and Neonates	12016
		5		Patient Populations At Risk	12020
			a	Congenital Immunodeficiency Syndromes	12024
			b	Malignancies	12028
			c	Hematopoietic Progenitor Cell Transplants	12032
			d	Solid Organ Transplants	12036
		6		Immunocompetent Patients – Risk Factors	12040
		7		Clinical Presentation and Diagnosis	12044
		8		Treatment	12048
		9		Prevention	12052
	D			Transfusion-Induced Iron Overload	12056
		1		Pathophysiology	12060
		2		Iron Burden of Transfusions	12064
		3		Clinical Features	12068
		4		Measurement of Iron Burden	12072
		5		Management	12076
			a	Goals	12080
			b	Chelation Therapy	12084
	E			Transfusion-Related Acute Lung Injury	12088
		1		Incidence and Epidemiology	12092
		2		Clinical Features	12096
		3		Pathophysiology	12100
			a	Acute Lung Injury - Features	12104
			b	Causes	12108
			c	Mechanisms of Lung Damage	12112
			d	Multiple Hit/Threshold Theory	12116
		4		Diagnosis and Differential Diagnosis	12120

				a	Clinical, Physiologic, Radiologic, and Laboratory Features	12124
				b	Consensus Definition	12128
			5		Treatment and Management	12132
			6		Donor Investigation	12136
			7		Prevention	12140
	F				Posttransfusion Purpura	12160
			1		Pathophysiology and Clinical Features	12164
			2		Treatment	12168
	G				Transfusion-Associated Dyspnea	12180
6					Plasma Components and Derivatives	12200
	A				Plasma Composition	12204
			1		General Features and Factors Influencing Plasma Composition	12208
			2		Albumin	12212
			3		Immunoglobulins	12216
			4		Alpha-1-Antitrypsin	12220
			5		C1 Inhibitor	12224
			6		Von Willebrand Factor Cleaving Protease	12228
			7		Coagulation Factors, Coagulation Factor Inhibitors, and von Willebrand Factor e.g. description, half-life	12232
	B				Preparation of Plasma Derivatives	12236
			1		Plasma Procurement	12240
			2		Plasma Manufacture	12244
			3		Pathogen Inactivation/Removal	12248
			4		Plasma Products – Indications and Clinical Use	12252
				a.	Prothrombin Complex Concentrate (PCC)	12253
			5		Adverse Effects	12256
			6		Industry Safety Programs	12260
			7		Recombinant DNA Technology and Manufacturing	12264
				a.	Recombinant Factor Viiia	12265
	C				Plasma Transfusion and Use of Albumin and Rh Immune Globulin	12268
			1		Fresh Frozen, Frozen, Cryo-Poor, Thawed, and Stored Plasma	12272
				a	Manufacture and Features	12276
				b	Clinical Use, Indications and Guidelines for Use	12280
				i	Surgery	12284
				ii	Massive Transfusion, Trauma, and Disseminated Intravascular Coagulation	12288
				iii	Intensive care	12292
				iv	Liver Disease	12296
				v	Warfarin Reversal	12300
				vi	Therapeutic Apheresis	12304
				c	Dosing	12308
				d	Risks and Adverse Effects	12312
				e	Pathogen-Inactivated Plasma	12316
			2		Cryoprecipitate	12320
				a	Manufacture and Features	12324

				b	Clinical Use, Indications and Guidelines for Use	12328
				c	Risks and Adverse Effects	12332
			3	Albumin		12336
				a	Manufacture and Features	12340
				b	Clinical Use, Indications and Guidelines for Use	12344
				c	Risks and Adverse Effects	12348
			4	Rh Immune Globulin		12350
				a	Manufacture and Features	12354
				b	Clinical Use, Indications and Guidelines for Use	12358
				c	Risks and Adverse Effects	12362
			5	IVIG		12370
			6	Other Plasma Derivatives, e.g. CMV, IG, HBV,IG, ISG, Rabies IG		12380
				a	Alpha-1-Antitrypsin	12385
				b	C1 Inhibitor	12390
				c	Fibrinogen concentrates	12395
7	Infectious Hazards of Transfusion					12400
	A	Transfusion-Transmitted Hepatitis				12404
		1	Incidence			12408
		2	Hepatitis B Virus			12412
			a	Epidemiology		12416
			b	Transmission		12420
			c	Clinical Features		12424
				i	Acute Infection	12428
				ii	Chronic Infection	12432
			d	Serologic and Molecular Markers of Infection		12436
			e	Donor Testing and Counseling		12440
			f	Prevention		12444
			g	Treatment		12448
		3	Hepatitis C Virus			12452
			a	Epidemiology		12456
			b	Transmission		12460
			c	Clinical Features		12464
				i	Acute Infection	12468
				ii	Chronic Infection	12472
			d	Donor Testing and Counseling		12476
			e	Prevention		12480
			f	Treatment		12484
		4	Hepatitis A Virus			12488
			a	Epidemiology		12492
			b	Transmission		12496
			c	Clinical Features		12500
			d	Donor Testing and Counseling		12504
			e	Prevention		12508
			f	Treatment		12512
		5	Hepatitis D and Hepatitis E Virus			12516
			a	Epidemiology		12520

				b	Diagnosis					12524	
				c	Transmission					12528	
				d	Clinical Features					12532	
				e	Prevention					12536	
			6	Non-A, Non-B, Non-C Hepatitis							12540
	B	Retroviruses								12544	
			1	Overview							12548
			2	Human Immunodeficiency Virus							12552
				a	General Information and Epidemiology						12556
				b	Incidence and Prevalence Among Blood Donors						12560
				c	Window Period and Risk of Transmission						12564
				d	Donor Testing and Counseling						12568
				e	Clinical Features						12572
				f	Prevention						12576
				g	Treatment						12580
			3	Human T-Cell Lymphotropic Viruses (HTLV)							12584
				a	General Information and Epidemiology						12588
				b	Incidence and Prevalence Among Blood Donors						12592
				c	Window Period and Risk of Transmission						12596
				d	Donor Testing and Counseling						12600
				e	Clinical Features						12604
				f	Prevention						12608
				g	Treatment						12612
	C	Cytomegalovirus (CMV)								12616	
			1	General Information and Epidemiology							12620
			2	Incidence and Prevalence Among Blood Donors							12624
			3	Window Period and Risk of Transmission							12628
			4	Donor Testing and Counseling							12632
			5	Clinical Features							12636
			6	Prevention							12640
			7	Treatment							12644
			8	Other herpesviruses							12646
	D	Other Viruses								12648	
			1	Parvovirus B19							12652
				a	General Information and Epidemiology						12656
				b	Transmission						12660
				c	Clinical Features						12664
			2	West Nile Virus							12668
				a	General Information and Epidemiology						12672
				b	Transmission						12676
				c	Donor Testing and Counseling						12680
				d	Clinical Features						12684
				e	Prevention						12688
				f	Zika, Dengue and Chikungunya						12690
	E	Transfusion Transmission of Parasites								12692	
			1	Chagas' Disease							12696
				a	General Information and Epidemiology						12700
				b	Transmission						12704

				c	Donor Testing and Counseling	12708
				d	Clinical Features	12712
				e	Prevention	12716
		2	Malaria			12720
				a	General Information and Epidemiology	12724
				b	Transmission	12728
				c	Donor Testing and Counseling	12732
				d	Clinical Features	12736
				e	Prevention	12740
		3	Babesiosis			12744
				a	General Information and Epidemiology	12748
				b	Transmission	12752
				c	Donor Testing and Counseling	12756
				d	Clinical Features	12760
				e	Prevention	12764
				f	Treatment	12766
		4	Leishmaniasis			12768
				a	General Information and Epidemiology	12772
				b	Transmission	12776
				c	Donor Testing and Counseling	12780
				d	Clinical Features	12784
				e	Prevention	12788
	F		Bacterial Contamination of Blood Products			12792
		1	Red Blood Cells – Overview and Epidemiology			12796
		2	Allogeneic RBCs – Agents and Incidence			12800
		3	Autologous RBCs – Agents and Incidence			12804
		4	Plasma, Cryoprecipitate and Derivatives - Agents and Incidence			12808
		5	Platelets			12812
				a	Source of Contamination	12816
				b	Agents and Incidence	12820
				c	Clinical Features	12824
				d	Treatment	12828
				e	Prevention	12832
		6	Strategies to Reduce the Risk of Posttransfusion Sepsis			12836
				a	Donor Screening	12840
				b	Skin Preparation	12844
				c	Diversion	12848
				d	Apheresis Versus Whole Blood-Derived Platelets	12852
				e	Storage Time and Temperature	12856
				f	Bacterial Detection	12860
				g	Bacterial Elimination	12864
		7	Syphilis			12868
		8	Lyme Disease			12872
	G		Prion Diseases			12876
		1	General Information and Epidemiology			12880
		2	Transmission			12884
		3	Clinical Features			12888



			4	Risk Management – Donor Selection	12892
			5	Blood Component Processing	12896
			6	Plasma Derivative manufacture	12900
			7	Cellular, Tissue, and Organ Transplantation	12904
	H			Pathogen Inactivation	12908
			1	Overview and description	12912
			2	Plasma	12916
				a Solvent/Detergent Treatment	12920
				b Methylene Blue Light Treatment	12924
				c Psoralen Ultraviolet Light Treatment	12928
				d Riboflavin Light Treatment	12932
			3	Platelet	12936
				a Psoralen Ultraviolet Light Treatment	12940
				b Riboflavin Light Treatment	12944
				c Thionine Light Treatment	12948
			4	Red Cell	12952
				a Alkylating Agents	12956
				b Photosensitizers	12960
				c Riboflavin Light Treatment	12964
			5	Emerging Technologies	12968
8				<b>Blood Donors and Blood Collection</b>	<b>13000</b>
	A			Recruitment and Screening of Donors and the Collection, Processing and testing of Blood	13004
			1	Organization of Blood Services	13008
				a United States	13012
				b Outside United States	13016
			2	Blood Donor Recruitment	13020
			3	Collection Process	13024
				a Donor Evaluation	13028
				i Consent	13032
				ii History and Physical Examination	13036
				iii Laboratory Testing	13040
				iv Deferral Criteria	13044
				b Blood Collection	13048
				i Whole Blood	13052
				ii Component Separation	13056
				iii Leukocyte Reduction	13060
				iv Automated Collection	13064
				c Blood Component Testing	13068
				i ABO/Rh	13072
				ii Antibody Screening	13076
				iii Infectious Disease	13080
				d Distribution	13084
				e Source Plasma	13088
			4	Blood Donor Adverse Events	13092
				a Donor Reactions	13096
				i Categories	13100
				ii Incidence	13104
				iii Clinical Features	13108
				iv Risk Factors	13112

					v	Treatment			13116
					vi	Prevention			13120
				b	Phlebotomy-Related				13124
					i	Categories			13128
					ii	Incidence			13132
					iii	Clinical Features			13136
					iv	Risk Factors			13140
					v	Treatment			13144
					vi	Prevention			13148
				c	Long-Term Effects of Donation				13152
					i	Iron			13156
					ii	Platelets			13160
					iii	Plasma Proteins			13164
9	Management, Quality, Legal, & Regulatory Issues in Transfusion Med. & Transplantation								13200
	A	Current Legal Issues							13204
		1	Blood Transfusion Injury Claims						13208
			a	Blood Shield Laws					13212
			b	Negligence					13216
			c	Standard of Care					13220
			d	Causation					13224
			e	Informed Consent					13228
		2	Donor Injury						13232
		3	Cord Blood						13236
		4	Tissue Banking						13240
		5	HIPAA Privacy Rule						13244
	B	Current Good Manufacturing Practice							13248
		1	General Overview						13252
		2	Licensing Products and Establishments						13256
		3	Recalls and FDA Enforcement Activities						13260
		4	Safety Initiatives						13264
		5	Enforcement Options						13268
		6	Rationale						13272
			a	Standard Operating Procedures					13276
			b	Record Keeping					13280
			c	Personnel and Training					13284
			d	Calibration					13288
			e	Validation					13292
			f	Labeling					13296
			g	Error Management					13300
			h	Quality Control Unit and Internal Audits					13304
			i	Facilities and Equipment					13308
			j	Process and Production Controls					13312
		7	Information Management						13316
		8	Common Violations						13320
	C	Transplant Organizations and Networks in the Regulation of Cellular and Tissue Therapy Programs							13324
		1	Hematopoietic Progenitor Cells						13328
			a	Sources					13332
			b	Indications					13336

					c	HLA Matching				13340
					d	Donor Registries and Networks				13344
					e	Outcomes Registries, Professional Associations and Networks				13348
					f	Accrediting Organizations				13352
			2			Other Cellular Therapies				13356
					a	Organizational Aspects				13360
					b	Accreditation and Regulation				13364
			3			Tissue Banks				13368
					a	Organizational Aspects				13372
					b	Accreditation and Regulation				13376
			D			Hospital Transfusion Services, Transfusion Committee and Quality Assurance				13380
				1		Role of the Medical Director				13384
					a	Administrative				13388
					b	Clinical				13392
					c	Education				13396
				2		Quality Assurance				13400
					a	Process Control				13404
					b	Error Management				13408
					c	Improving Transfusion Practice				13412
				3		Regulatory and Accreditation Requirements				13416
					a	Food and Drug Administration				13420
					b	AABB				13424
					c	Joint Commission				13428
					d	College of American Pathologists				13432
				4		Transfusion Committee				13436
					a	Membership				13440
					b	Functions				13444
					c	Oversight of Transfusion Policies, Procedures, and Guidelines				13448
					d	Education				13452
			E			Other Administrative Issues				13455
10						Surgery Patients				13500
			A			Alternatives to Transfusion: Perioperative Blood Management				13504
				1		Preoperative				13508
					a	Autologous Blood Donation				13512
					b	Anemia optimization				13516
						i	Iron			13520
						ii	Erythropoietin			13524
				2		Intraoperative/Postoperative				13528
					a	Acute Normovolemic hemodilution				13532
					b	Intraoperative autologous blood recovery and reinfusion (cell salvage)				13536
					c	Postoperative autologous blood recovery and reinfusion				13540
			B			Hemostasis for Surgery/Invasive Procedures				13544
				1		Preprocedure Blood Components				13548
					a	Common Laboratory tests of Hemostasis and Their Relationship With Procedure-related Bleeding				13552

										b	Procedure-Related Bleeding	13556
										i	Central Venous Catheter	13560
										ii	Liver Biopsy	13564
										iii	Thoracentesis and Paracentesis	13568
										iv	Gastrointestinal Endoscopy and Biopsy	13572
										v	Procedures on Upper Airway, Bronchoscopy, and Transbronchial Lung Biopsy	13576
										vi	Renal Biopsy	13580
										vii	Epidural Anesthesia, Lumbar Puncture, and Neurosurgical Procedures	13584
										viii	Angiography	13588
				2							Treatment of Bleeding	13592
										a	Local	13596
										i	Physical – Sutures, Electrocautery, Compression, Direct Packing, etc	13600
										ii	Topical Agents	13604
										iii	Topical Sealants	13608
										iv	Topical Thrombin	13612
										v	Topical Antifibrinolytics	13616
										b	Generalized	13620
										i	Skin and Membrane	13624
										ii	Purpura and Soft Tissue	13628
										iii	Small Vessel Bleeding During Surgery	13632
										iv	DDAVP	13634
				C							Transfusion Therapy for Trauma and Burn Patients	13636
										1	Shock	13640
										a	General Information and Definition	13644
										b	Hemorrhagic Shock and Classification	13648
										i	Acidosis	13652
										ii	Hypothermia	13656
										iii	Coagulopathy	13660
										c	Trauma Patient	13664
										i	Initial Resuscitation	13668
										aa	Damage Control	13672
										ab	Blood Component Therapy	13676
										ac	Hemostatic Agents	13680
										ad	Pharmacologic Agents	13684
										ii	Intraoperative	13688
										aa	Damage Control	13692
										ab	Temperature	13696
										ac	Blood Component Therapy	13700
										ad	Autotransfusion	13704
										ae	Solid Organ Injury	13708
										af	Hemostatic Agents	13712
										ag	Pharmacologic Agents	13716
										iii	Recovery Phase	13720
										aa	Blood Component Therapy	13724
										iv	Massive Transfusion	13728
										aa	Definition	13732

									ab	Blood Component Therapy	13736
									ac	Complications	13740
						d				Burn Patient	13744
								i		Initial Resuscitation	13748
									aa	Fluid Therapy	13752
										1	Colloid
										2	Crystalloid
									ab	Transfusion Therapy	13764
									ac	Hemostatic Agents	13768
									ad	Pharmacologic Agents	13772
		D								Transfusion Therapy in Solid Organ Transplantation	13776
						1				Organ Procurement and Transplants	13780
						2				Immunologic Barriers – ABO and HLA	13784
								a		Management Across Immunologic Barriers	13788
								b		Organ Selection	13792
								c		Plasma Exchange	13796
								d		Pharmacologic Agents	13800
						3				Immunohematology	13804
								a		Patient Alloantibodies	13808
								b		Passenger Lymphocyte Antibodies	13812
						4				Transfusion Therapy	13816
								a		Liver	13820
								b		Heart	13824
								c		Lung	13828
								d		Kidney	13832
								e		Pancreas	13836
								f		Other	13840
						5				Special Needs	13844
								a		CMV Low Risk	13848
								b		Leukocyte Reduction	13852
								c		Irradiation	13856
		11								Biovigilance	13900
						A				Biovigilance/Hemovigilance	13904
								1		Requirements for Effective Program	13908
								2		Scope	13912
									a	What Should Be Reported	13916
									i	Adverse Reactions	13920
									ii	Adverse Incidents	13924
									iii	Near Misses	13928
									b	Biovigilance	13932
									i	Passive Reporting Versus Active Surveillance	13936
									ii	Traceability	13940
									c	Blood Donors	13944
									d	Transfusion Recipients	13948
						B				Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion	13952
								1		Concepts and Overview	13956
								2		Laboratory Features	13960
								3		Beneficial Clinical Effects	13964

				a	Enhanced Survival of Renal Allografts	13968
				b	Reduced Risk of Recurrent Spontaneous Abortions	13972
				c	Reduced Risk of recurrence of Crohn's Disease	13976
			4		Deleterious Clinical Effects	13980
				a	Increased Recurrence of Resected Malignancies	13984
				b	Increased Risk of Postoperative Bacterial Infection	13988
				c	Increased Risk of Short-Term Mortality	13992
<b>12 Platelets and Platelets Components</b>						<b>14000</b>
	A	Platelet Production (Thrombopoiesis)				14004
		1	Megakaryocyte Development, Maturation, and Differentiation			14008
		2	Thrombopoietic/Megakaryocyte/Hematopoietic Growth Factors			14012
		3	Genetic and Cellular Regulation of Thrombopoiesis			14016
		4	Platelet Production/Shedding/Release			14020
	B	Platelet immunology				14024
		1	Platelet Antigens (ABO, HLA, Platelet Specific)			14028
		2	Disorders of Platelet Alloimmunization			14032
		3	Platelet Autoimmunity			14036
	C	Platelets in the Bloodstream				14040
		1	Platelet Circulation/Distribution/Destruction			14044
		2	Platelet Survival/Kinetics in Health and Disease			14048
	D	Platelets and Hemostasis				14052
		1	Normal Platelet Plug and Clot Formation			14056
		2	Genetic/Congenital Platelet Disorders			14060
		3	Acquired Platelet Disorders			14064
	E	Platelet Transfusions				14068
		1	Collection and Storage of Platelet Preparations/Concentrates			14072
		2	Clinical Platelet Transfusions (Indications, Dose and Schedule)			14076
		3	Alternatives to Platelet Transfusions (Thrombopoietic and Pharmacologic agents)			14080
<b>13 Neutrophils and Granulocyte Components</b>						<b>14100</b>
	A	Neutrophil Production (Myelopoiesis)				14104
		1	Neutrophil Development, Maturation and Differentiation			14108
		2	Myelopoietic/Hematopoietic Growth Factors			14112
		3	Genetic and Cellular Regulation of Myelopoiesis			14116
		4	Neutrophil Release, Compartments and Circulating Kinetics			14120
	B	Neutrophil Immunology				14124
		1	Neutrophil Antigens (ABO, HLA, Neutrophil Specific)			14128
		2	Disorders of Neutrophil Alloimmunization and Autoimmunity			14132
	C	Neutrophils and Infections				14136
		1	Neutrophil Response to Infections			14140

			2	Neutrophil Antimicrobial Functions						14144
			3	Neutrophil Congenital and Acquired disorders						14148
		D		Neutrophil/Granulocyte Transfusions (Primarily Clinical Issues)						14152
			1	Neutrophil Collection, Storage and Transfusion						14156
			2	Alternatives to Neutrophil Transfusions (Myelopoietic Factors)						14160
14				Intravascular Cell Kinetics						14200
		A		Concepts of Post-Transfusion Recovery and Tracking Labeled/Tracer cells						14204
		B		Techniques of Radiolabeling Blood Cells (RBCs, Platelets and Leukocytes)						14208
		C		Use of Non-Radioactive Cellular Labels						14212
		D		Methods/Calculations for Determining Intravascular Cell Kinetics						14216
		E		Cell Kinetic Applications in Health and Disease						14220
15				Obstetric and Pediatric Patients						14300
		A		Obstetric Transfusion Practices						14304
			1	Maternal Hematologic Disorders During Pregnancy						14308
			2	Maternal Hemorrhage and Transfusions During Pregnancy						14312
			3	Fetal (Intrauterine) Transfusions						14316
		B		Hemolytic Disease of the Fetus and Newborn						14320
			1	ABO Incompatibility						14324
			2	Rh(D) and Other Fetal-Maternal RBC Incompatibilities						14328
			3	Fetal RBC Membrane/Metabolic or Hemoglobin Abnormalities						14332
			4	Management						14336
				a	Diagnostic and Surveillance Tests					14340
				b	Fetal and Neonatal Transfusions, Phototherapy, IVIG, etc)					14344
		C		Congenital Disorders of Clotting and Anticoagulant Proteins						14348
			1	Developmental Physiology of Plasma Proteins						14352
			2	Hemophilia A, B and von Willebrand Disease (Pathophysiology and Treatment)						14356
				a	DDAVP				stet	13634
			3	Congenital Disorders of Non-Hemophilia Clotting Proteins						14360
			4	Congenital Disorders of Anticoagulant/Prothrombotic Proteins						14364
		D		Congenital Hemoglobinopathies and Hemolytic Anemias						14368
			1	Sickle Cell Disease (Pathophysiology and Treatment)						14372
			2	Non-Sickle Cell Hemoglobinopathies						14376
			3	Thalassemias (Pathophysiology and Treatment)						14380
			4	Congenital Red Cell Membrane and Enzyme Defects						14382
		E		Neonatal Transfusions						14384
			1	Anemia of Prematurity (Pathophysiology and Treatment)						14388
			2	Thrombocytopenia of Prematurity (Pathophysiology and Treatment)						14392
			3	Neonatal Blood Banking Practices (Dedicated Units, WBC-Reduction, Irradiation, etc)						14396

			4	Neonatal/Infant Plasma, Cryoprecipitate and Neutrophil Transfusions	14400	
	F	Congenital Disorders of Hematopoiesis			14404	
16	Hematopoietic Progenitor Cell (HPC) Transplantation				14500	
	A	Biology of Marrow Transplantation – Indications, Methods, Results, Adverse Effects			14504	
		1	Autologous		14508	
		2	Allogeneic / Syngeneic		14512	
	B	Biology of HPC and HPC Transplantation			14516	
		1	HPC Biology		14520	
		2	Identification and Measurement of HPC		14524	
		3	Allogeneic/Syngeneic Donor Selection, Qualification, Eligibility		14528	
		4	HLA Typing for HPC Transplantation		14532	
		5	Processing Requirements for HPC		14536	
			a	General	14540	
			b	Patient-Specific	14544	
		6	Regulatory, Compliance, Accreditation		14548	
	C	HPC Sources and Collection			14552	
		1	HPC - Marrow		14556	
			a	Methods of Harvesting	14560	
			b	Characteristics,	14564	
			c	Adverse Effects	14568	
		2	HPC – Apheresis – Characteristics and Adverse effects		14572	
			a	Biology of Stem Cell Mobilization	14576	
			b	Mobilization Regimens (Indications, Dose, Schedule, Efficacy, Adverse Effects)	14580	
				i	Chemotherapy	14584
				ii	Growth Factors – G-CSF, GM-CSF	14588
				iii	Adhesion blockers – Plerixafor	14592
			c	Scheduling Mobilization and Apheresis Collection	14596	
			d	Monitoring Mobilization and HPC Collection	14600	
			e	Collection of Lymphocytes for Infusion (Donor Lymphocyte Infusion; DLI)	14604	
			f	Apheresis Considerations – Techniques, Vascular Access, Donor Management, and Adverse Effects (Allogeneic vs	14608	
		3	HPC - Cord Blood - Characteristics, and Methods		14612	
			a	Cord Blood Banking - Donor Eligibility, Collection Methods, Processing, Testing, Cryopreservation	14616	
			b	Cord Blood Unit Characteristics	14620	
			c	Donor Selection for Transplant (Unrelated and Related)	14624	
		4	Selection of the Appropriate HPC Source for a Given Patient		14628	
	D	HPC Processing - Goals, Guidelines, and Methods (preparation for infusion)			14632	
		1	HPC for Autologous Transplants		14636	



			2	HPC for Allogeneic Transplant – Indications for Plasma, RBC Reduction,	14640
			3	Preparation of Cells for Donor Lymphocyte Infusion (DLI)	14644
			4	Cord Blood	14648
			5	Processing of Other CT Products (eg Antigen-Directed T cells, Marrow Stromal Cells)	14652
	E	HPC Storage and Preservation			14656
			1	Liquid Storage and Transport - Anticoagulant, Time, Temperature, Preservative, Cell Concentration	14660
			2	Rationale for Cryopreservation	14664
			3	Cryopreservation Theory and Practice	14668
				a Cryoprotectants	14672
				b Cryopreservation Techniques – Controlled Rate, "Dump Freeze"	14676
				c Storage - Mechanical and Liquid Nitrogen (Vapor vs Liquid),	14680
	F	Management of RBC Antigen Incompatibility in Allogeneic Transplantation - ABO/Rh, HLA, Other			14684
			1	Graft Management - Depletion of RBC (Major), Plasma (Minor)	14688
			2	Patient Transfusion Management	14692
				a Major or Minor ABO Incompatibility – Immediate vs Delayed Hemolysis	14696
				b Passenger Lymphocyte Syndrome (PLS), Cause, Diagnosis, Course, Therapy, Prevention	14700
			3	Ablative vs Non-Ablative (Immunosuppressive) Conditioning	14704
			4	Pediatric Considerations for Graft Manipulation	14708
	G	HPC Assessment - Pre- and Post-Processing and Post-Thaw			14712
			1	Cell Counts and Methods	14716
			2	HPC Measurement and Enumeration	14720
				a Flow Cytometry CD34+ Cells and Other Markers (Single vs Dual platform)	14724
				b Non-Flow Methods	14728
			3	HPC Viability Assessment Techniques	14732
			4	HPC Cell Culture Assays	14736
			5	HPC Functional and Differentiation Assays	14740
			6	HPC Microbial Assessment - Gram Stain, Cultures - Aerobic, Anaerobic, Fungal	14744
	H	Cell Selection Methods and Applications			14748
			1	Positive and Negative Selection - Techniques, Results, Indications	14752
			2	CD34 Cells and Others (eg Treg)	14756
			3	Tumor Purging and T Cell Depletion	14760
	I	HPC and CTP Thawing and Post-Thaw Processing (Apheresis, Marrow, Cord Blood, etc)			14764
			1	Direct HPC Infusion vs Pre-Infusion Cell Washing	14768
			2	Special Considerations for Preparation of Cord Blood HPC for infusion	14772
	J	HPC and CTP infusion			14776

			1	General Guidelines – Filters, No Irradiation, Infusion Rate, DMSO Limits, Infusion Pumps	14780
			2	Adverse Effects and Infusion Reactions – Incidence, Causes, Diagnosis, Management	14784
			3	Management and Infusion of Contaminated Products	14788
	K	Engraftment			14792
			1	Definition, Chimerism, Relationship to CD34+ Cell Doses	14796
			2	Rates - Autologous vs Allogeneic, Related vs MUD, HPC Source, Conditioning	14800
			3	Engraftment failure – Causes, Management	14804
			4	Immune Reconstitution Post-Transplant	14808
			5	Donor Lymphocyte Infusion – Rationale, Efficacy	14812
	L	HPC Lab quality assurance and accreditation - AABB, FACT, CAP, NMDP			14816
			1	Regulatory Considerations – Federal GMP, GTP; State	14820
	M	Laboratory Administration - Staff Hiring and Training, Facilities, Equipment, Supplies, Laboratory Development, Deviations, Non-Conforming HPC and			14824
	N	Experimental Cell Therapies			14828
			1	Institutional vs Commercially Sponsored	14832
			2	Types (eg Marrow Stromal, Adoptive Therapy with T Cells, Gene-Modified Cells)	14836
			3	Special Requirements for Processing (Clean Room, etc)	14840
			4	Regulatory Considerations	14844